UBS Group’s Impact BioMedical IBO Stock Holding History
Bought
Maintained
Sold
Other funds holding IBO
UBS Group's IBO Position: Q3 2026 in Review
UBS Group increased its Impact BioMedical (IBO) stake by 57% in Q3 2026, buying an estimated $638 and bringing the position to 299 shares worth $1.67K. The position accounts for ﹤0.01% of the portfolio, ranked #10195.
UBS Group first reported a position in IBO in Q4 2024 and has held it in 8 quarters since. The position peaked at $25.7K in Q2 2025. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.
- UBS Group held 299 shares of Impact BioMedical worth $1.67K as of Q3 2026.
- UBS Group bought 109 Impact BioMedical shares in Q3 2026, an estimated $638.
- Impact BioMedical made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10195 holding.
- UBS Group first reported a position in Impact BioMedical in Q4 2024 and has held it in 8 quarters since.
- UBS Group's Impact BioMedical position peaked at $25.7K in Q2 2025.
- 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.